Ebola and Marburg virus vaccines (Q30234637)

11 June 2017

1 reference

23 October 2022

Ebola and Marburg virus vaccines (English)

1 reference

11 June 2017

0 references

Orthoebolavirus zairense

0 references

0 references

Andrea Marzi

2

0 references

author name string

Pierce Reynolds

series ordinal

1

1 reference

11 June 2017

publication date

26 April 2017

1 reference

11 June 2017

1 August 2017

1 reference

23 October 2022

2 references

Prospects for immunisation against Marburg and Ebola viruses

11 June 2017

23 October 2022

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Inactivated vaccine for Ebola virus efficacious in guineapig model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Evaluation in nonhuman primates of vaccines against Ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Antigenicity and Vaccine Potential of Marburg Virus Glycoprotein Expressed by Baculovirus Recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Replication-deficient ebolavirus as a vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Generation of biologically contained Ebola viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Ebola virus vaccines: an overview of current approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Development of a new hydrogen peroxide–based vaccine platform.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Hydrogen peroxide inactivation of influenza virus preserves antigenic structure and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Characterization of CD8 T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

21 January 2018

Ebola haemorrhagic fever

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Development of a preventive vaccine for Ebola virus infection in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Generation of an adenoviral vaccine vector based on simian adenovirus 21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, doub

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

The Final (Oral Ebola) Vaccine Trial on Captive Chimpanzees?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Successful topical respiratory tract immunization of primates against Ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

CD8 cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Ebola virus-like particles protect from lethal Ebola virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Induction of humoral and CD8 T cell responses are required for protection against lethal Ebola virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Impact of Systemic or Mucosal Immunity to Adenovirus on Ad-Based Ebola Virus Vaccine Efficacy in Guinea Pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Effective post-exposure treatment of Ebola infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Protection against lethal challenge by Ebola virus-like particles produced in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11262-017-1455-X

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

21 January 2018

1 reference

12 December 2020

Ebola virus vaccines - reality or fiction?

1 reference

12 December 2020

Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses

1 reference

12 December 2020

Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections

1 reference

12 December 2020

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus

1 reference

12 December 2020

10.1007/S11262-017-1455-X

Identifiers

DOI

1 reference

Dimensions Publication ID

11 June 2017

1085072679

0 references

PMC publication ID

7089128

0 references

1 reference